Welcome to our dedicated page for Eton Pharmaceuticals SEC filings (Ticker: ETON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical trial results, orphan-drug exclusivity tables, and complex royalty agreements often bury the numbers that matter in Eton Pharmaceuticals’ SEC disclosures. If you have ever opened a 10-K and asked, “Where does the pipeline spending really go?” or searched EDGAR for Eton Pharmaceuticals insider trading Form 4 transactions, you already know the challenge.
Stock Titan solves it. Our AI reads every Eton Pharmaceuticals quarterly earnings report 10-Q filing, pulls out revenue by marketed rare-disease therapy, and flags new risk factors—giving you clear, plain-language summaries in minutes. Need real-time alerts? The platform streams Eton Pharmaceuticals Form 4 insider transactions real-time so you can see executive stock moves as they happen. You’ll also find:
- Eton Pharmaceuticals annual report 10-K simplified with section-by-section commentary
- 8-K headlines such as FDA approvals or licensing deals—Eton Pharmaceuticals 8-K material events explained
- Proxy statement insights into Eton Pharmaceuticals proxy statement executive compensation
Whether you’re tracking hydrocortisone formulation milestones or comparing insider confidence across quarters, our coverage of every form—10-K, 10-Q, 8-K, S-3, and the ever-important Eton Pharmaceuticals executive stock transactions Form 4—is continuously updated. Investors use these tools to monitor pipeline progress, validate orphan-drug exclusivity timelines, and perform Eton Pharmaceuticals earnings report filing analysis without wading through hundreds of pages. If you’re understanding Eton Pharmaceuticals SEC documents with AI for the first time or just need a faster workflow, our platform turns dense filings into actionable clarity.
Eton Pharmaceuticals filed a Form S-8 to register 1,068,363 additional shares of common stock under its 2018 Equity Incentive Plan and 150,000 additional shares under its 2018 Employee Stock Purchase Plan. These shares expand the pool available for employee equity awards and stock purchases, supporting compensation and retention programs. The company notes it previously registered 7,699,634 shares under the 2018 Equity Incentive Plan and 1,050,000 shares under the 2018 ESPP on earlier Form S-8 filings, and incorporates its latest Annual Report, Quarterly Reports, and specified Current Reports by reference.
Eton Pharmaceuticals, Inc. filed an amended Form 8-K to add required financial information related to its completed acquisition of the Increlex® product rights from Ipsen S.A. The amendment supplies audited abbreviated financial statements for INCRELEX as of and for the years ended December 31, 2022 and 2023, along with unaudited abbreviated financial statements as of September 30, 2024 and for the nine months ended September 30, 2023 and 2024. It also includes unaudited pro forma condensed combined financial statements for Eton and INCRELEX for the nine-month periods ended September 30, 2023 and 2024, helping readers see how the acquisition would have affected the company’s historical financials. Other disclosures in the original report remain unchanged.
Eton Pharmaceuticals reported third‑quarter results. Net revenues were $22.459 million, driven by product sales and royalties. Gross profit reached $7.855 million. The quarter recorded a net loss of $1.927 million, or $0.07 per share. For the nine months, net revenues were $58.669 million with a net loss of $6.084 million.
Cash and cash equivalents were $37.121 million as of September 30, 2025, up from $14.936 million at year‑end, supported by $22.075 million in operating cash flow year‑to‑date. Current liabilities rose to $44.183 million, including higher accounts payable and Medicaid rebate accruals, and long‑term debt stood at $27.591 million. Customer concentration remains significant: AnovoRx represented 85.8% of net product revenues for the nine months and 65.8% of net accounts receivable as of September 30, 2025. The company also recorded intangible amortization tied to recent product acquisitions and recognized partial licensing revenue with Esteve related to INCRELEX.
Eton Pharmaceuticals furnished an 8-K announcing its financial results for the third quarter ended September 30, 2025. The company issued a press release, attached as Exhibit 99.1. The filing also discusses the use of non-GAAP Adjusted EBITDA, which management uses for planning, evaluating performance, communicating with the board and investors, and assessing acquisitions and comparative net sales. The information in Item 2.02 and Exhibit 99.1 is furnished, not filed, and is not incorporated by reference.
Eton Pharmaceuticals CFO James R. Gruber reported sales of company stock on August 19 and August 20, 2025. The Form 4 shows he sold 39,082 shares on 08/19/2025 at a weighted average price of $16.16 and 2,631 shares on 08/20/2025 at a weighted average price of $16.02, for total shares sold of 41,713. Following those transactions his beneficial ownership is reported as 205,299 shares after the 08/19 trade and 204,753 shares after the 08/20 trade, held directly. The filing is signed and dated 08/20/2025 and includes an explanation that trade details by price are available on request.
Eton Pharmaceuticals filed a Form 144 notifying the proposed sale of 41,713 shares of its common stock through Raymond James & Associates on the NASDAQ, with an aggregate market value of $692,645 and an approximate sale date of 08/18/2025. The notice lists the securities' acquisition history: seven lots acquired between 12/09/2022 and 12/10/2024 via ESPP payroll purchases and company grants, totaling the units shown. The filer reports no securities sold in the past three months and includes the standard representation that they are not aware of undisclosed material adverse information about the issuer.
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) filed a Form 8-K to disclose a material event under Item 8.01. On 8 July 2025, the company announced that the U.S. Food and Drug Administration (FDA) accepted for review its New Drug Application (NDA) for ET-600, a proprietary, patented oral solution formulation of desmopressin. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of 25 February 2026.
The acceptance of the NDA formally places ET-600 into the FDA review queue and confirms that the submission is sufficiently complete for substantive review. While no financial data were provided in this filing, ET-600 represents a potential commercial asset that could expand Eton’s rare disease/critical care portfolio if ultimately approved. The company attached the related press release as Exhibit 99.1 and provided routine exhibit and signature information.
Key points for investors:
- NDA accepted: De-risks the regulatory pathway by moving ET-600 from development to formal FDA review.
- PDUFA date set: Establishes a definitive decision timeline (≈7.5 months from filing date).
- No financial metrics: The 8-K contains no sales, earnings, or cost guidance related to ET-600 or the broader business.
- Next catalyst: Potential FDA approval decision on or before 25 February 2026.
The filing is non-dilutive—it involves no financing, equity issuance, or debt—and does not alter previously reported financial statements. Nonetheless, regulatory progress on ET-600 can influence future revenue forecasts and valuation multiples once market potential data are released.
Eton Pharmaceuticals (NASDAQ:ETON) filed an 8-K to disclose that the company will be added to the Russell 3000 and Russell 2000 indexes effective after the U.S. market close on June 27 2025.
The filing, made under Item 8.01, includes a press release (Exhibit 99.1) and signals broader passive fund ownership, higher trading liquidity and increased institutional visibility. No financial results, strategic shifts or governance changes were reported.
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) filed a Form 8-K to disclose an auditor transition effective 13 June 2025.
Dismissal of Crowe LLP: The Audit Committee terminated Crowe LLP after only one audit cycle (FY-2024). Crowe’s 2024 opinion was clean (no adverse or qualified opinion), and the firm reported no disagreements or reportable events with management under Item 304(a)(1) of Regulation S-K. Crowe’s required concurrence letter is attached as Exhibit 16.1.
Appointment of Grant Thornton LLP: The Audit Committee simultaneously engaged Grant Thornton LLP as the new independent registered public accounting firm for FY-2025. The company confirms that, during FY-2023, FY-2024, and the subsequent interim period, it did not consult Grant Thornton on any accounting matters or potential opinions prior to the appointment.
Investor takeaways:
- The change appears procedural; the absence of disagreements reduces immediate red-flag risk.
- Auditor turnover after one year may still prompt investors to monitor governance continuity and upcoming audit fees or timelines.
- No financial restatements, outlook changes, or earnings data were disclosed in this filing.
FAQ
What is the current stock price of Eton Pharmaceuticals (ETON)?
What is the market cap of Eton Pharmaceuticals (ETON)?
